Study identifier:NIS-RES-PUL-2007/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Utilization patterns of Pulmicort HFA in real life practice
asthma
-
No
-
All
260
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2010 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to identify the potential issues during short and mid term utilization of Pulmicort hydro fluoroaklane (HFA) pressurized metered-dose inhaler (pMDI)and describe associated factors.
Location
Location
Alcorcon, Madrid, Spain
Location
Barcelona, Barcelona, Spain
Location
Fuentes de Ebro, Zaragoza, Spain
Location
Leganes, Madrid, Spain
Location
Madrid, Madrid, Spain
Location
Murcia, Murcia, Spain
Location
Olivares, Sevilla, Spain
Location
Sabadell, Barcelona, Spain
Arms | Assigned Interventions |
---|---|
1 Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.